Literature DB >> 22293773

2011 recommendations for the diagnosis and management of gout and hyperuricemia.

Max Hamburger1, Herbert S B Baraf, Thomas C Adamson, Jan Basile, Lewis Bass, Brent Cole, Paul P Doghramji, Germano A Guadagnoli, Frances Hamburger, Regine Harford, Joseph A Lieberman, David R Mandel, Didier A Mandelbrot, Bonny P McClain, Eric Mizuno, Allan H Morton, David B Mount, Richard S Pope, Kenneth G Rosenthal, Katy Setoodeh, John L Skosey, N Lawrence Edwards.   

Abstract

Gout is a major health problem in the United States; it affects 8.3 million people, which is approximately 4% of the adult population. Gout is most often diagnosed and managed in primary care practices; thus, primary care physicians have a significant opportunity to improve patient outcomes. Following publication of the 2006 European League Against Rheumatism (EULAR) gout guidelines, significant new evidence has accumulated, and new treatments for patients with gout have become available. It is the objective of these 2011 recommendations to update the 2006 EULAR guidelines, paying special attention to the needs of primary care physicians. The revised 2011 recommendations are based on the Grading of Recommendations Assessment, Development, and Evaluation approach as an evidence-based strategy for rating quality of evidence and grading the strength of recommendation formulated for use in clinical practice. A total of 26 key recommendations, 10 for diagnosis and 16 for management, of patients with gout were evaluated, resulting in important updates for patient care. The presence of monosodium urate crystals and/or tophus and response to colchicine have the highest clinical diagnostic value. The key aspect of effective management of an acute gout attack is initiation of treatment within hours of symptom onset. Low-dose colchicine is better tolerated and is as effective as a high dose. When urate-lowering therapy (ULT) is indicated, the xanthine oxidase inhibitors allopurinol and febuxostat are the options of choice. Febuxostat can be prescribed at unchanged doses for patients with mild-to-moderate renal or hepatic impairment. The target of ULT should be a serum uric acid level that is ≤ 6 mg/dL. For patients with refractory and tophaceous gout, intravenous pegloticase is a new treatment option. This article is a summary of the 2011 clinical guidelines published in Postgraduate Medicine. This article provides a streamlined, accessible overview intended for quick review by primary care physicians, with the full guidelines being a resource for those seeking additional background information and expanded discussion.

Entities:  

Mesh:

Year:  2011        PMID: 22293773     DOI: 10.3810/psm.2011.11.1946

Source DB:  PubMed          Journal:  Phys Sportsmed        ISSN: 0091-3847            Impact factor:   2.241


  12 in total

1.  Serum Uric Acid Levels and Risk of Intracranial Atherosclerotic Stenosis: A Cross-Sectional Study.

Authors:  Lin Li; Jun-Xia Zhu; Xiao-He Hou; Ya-Hui Ma; Wei Xu; Chen-Chen Tan; Fu-Rong Sun; Hong-Qi Li; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2020-02-08       Impact factor: 3.911

2.  [Rheumatic diseases with initial manifestations in middle age: gout, rheumatoid arthritis and ANCA-associated vasculitides].

Authors:  S Kleinert; H P Tony
Journal:  Internist (Berl)       Date:  2012-09       Impact factor: 0.743

3.  Development and validation of a quantitative method for estimation of the urate burden in patients with gouty arthritis using dual-energy computed tomography.

Authors:  Maximilian Kotlyarov; Kay Geert A Hermann; Jürgen Mews; Bernd Hamm; Torsten Diekhoff
Journal:  Eur Radiol       Date:  2019-07-22       Impact factor: 5.315

4.  Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.

Authors:  Nan Liang; Mingshu Sun; Ruixia Sun; Ting Xu; Lingling Cui; Can Wang; Lidan Ma; Xiaoyu Cheng; Xiaomei Xue; Wenyan Sun; Xuan Yuan; Hui Zhang; Hailong Li; Yuwei He; Aichang Ji; Xinjiang Wu; Changgui Li
Journal:  Arthritis Res Ther       Date:  2019-09-02       Impact factor: 5.156

5.  Plasma Metabolic Profiling Analysis of Gout Party on Acute Gout Arthritis Rats Based on UHPLC-Q-TOF/MS Combined with Multivariate Statistical Analysis.

Authors:  Yuming Wang; Chenghao Bi; Wentao Pang; Yuechen Liu; Yu Yuan; Huan Zhao; Tianpu Zhang; Yungang Zhao; Yubo Li
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

6.  Rheumatologists' understanding of refractory gout: a questionnaire survey in China.

Authors:  Xinxin Han; Yue Yin; Yu Cao; Xiaotian Chu; Yingdong Han; Hong Di; Na Xu; Yun Zhang; Xuejun Zeng
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

7.  Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.

Authors:  Meida Fan; Jian Liu; Bingcheng Zhao; Xinyu Wu; Xuefeng Li; Jieruo Gu; Naomi Schlesinger
Journal:  Clin Rheumatol       Date:  2020-07-11       Impact factor: 2.980

8.  Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.

Authors:  Theodora Szasz; Robert Patrick Davis; Hannah S Garver; Robert J Burnett; Gregory D Fink; Stephanie W Watts
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

Review 9.  Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.

Authors:  Sabrina M Nielsen; Else M Bartels; Marius Henriksen; Eva E Wæhrens; Henrik Gudbergsen; Henning Bliddal; Arne Astrup; Filip K Knop; Loreto Carmona; William J Taylor; Jasvinder A Singh; Fernando Perez-Ruiz; Lars E Kristensen; Robin Christensen
Journal:  Ann Rheum Dis       Date:  2017-09-02       Impact factor: 19.103

10.  The Anti-Inflammatory and Uric Acid Lowering Effects of Si-Miao-San on Gout.

Authors:  Ling Cao; Tianyi Zhao; Yu Xue; Luan Xue; Yueying Chen; Feng Quan; Yu Xiao; Weiguo Wan; Man Han; Quan Jiang; Liwei Lu; Hejian Zou; Xiaoxia Zhu
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.